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Abstract
Objective To evaluate efficacy and safety outcomes in patients in the
PLATelet inhibition and patient Outcomes (PLATO) trial who at
randomisation were planned for a non-invasive treatment strategy.
Design Pre-specified analysis of pre-randomisation defined subgroup
of prospective randomised clinical trial.
Setting 862 centres in 43 countries.
Participants 5216 (28%) of 18 624 patients admitted to hospital for
acute coronary syndromewho were specified as planned for non-invasive
management.
Interventions Randomised treatment with ticagrelor (n=2601) versus
clopidogrel (2615).
Main outcome measurements Primary composite end point of
cardiovascular death, myocardial infarction, and stroke; their individual
components; and PLATO defined major bleeding during one year.
Results 2183 (41.9%) patients had coronary angiography during their
initial hospital admission, 1065 (20.4%) had percutaneous coronary
intervention, and 208 (4.0%) had coronary artery bypass surgery.
Cumulatively, 3143 (60.3%) patients had been managed non-invasively
by the end of follow-up. The incidence of the primary end point was lower
with ticagrelor than with clopidogrel (12.0% (n=295) v 14.3% (346);
hazard ratio 0.85, 95% confidence interval 0.73 to 1.00; P=0.04). Overall
mortality was also lower (6.1% (147) v 8.2% (195); 0.75, 0.61 to 0.93;
P=0.01). The incidence of total major bleeding (11.9% (272) v 10.3%
(238); 1.17, 0.98 to 1.39; P=0.08) and non-coronary artery bypass
grafting related major bleeding (4.0% (90) v 3.1% (71); 1.30, 0.95 to
1.77; P=0.10) was numerically higher with ticagrelor than with clopidogrel.
Conclusions In patients with acute coronary syndrome initially intended
for non-invasive management, the benefits of ticagrelor over clopidogrel
were consistent with those from the overall PLATO results, indicating
the broad benefits of P2Y12 inhibition with ticagrelor regardless of
intended management strategy.
Trial registration Clinical trials NCT00391872.
Introduction
In patients with non-ST elevation acute coronary syndromewith
moderate to high risk characteristics, current guidelines
recommend an invasive strategy with angiography followed by
percutaneous coronary intervention or coronary artery bypass
grafting if appropriate.1 2 However, the Invasive versus
Conservative Treatment in Unstable Coronary Syndromes
(ICTUS) trial supports a conservative, non-invasive strategy
with intensive medical treatment and invasive procedures only
in case of signs or symptoms of ischaemia,3 and this is
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considered an appropriate treatment strategy for non-ST
elevation acute coronary syndrome in patients at lower risk.1 A
considerable proportion of patients do not have angiography or
revascularisation during the initial hospital admission.4 5
However, dual antiplatelet treatment with aspirin and the P2Y12
inhibitor clopidogrel is recommended for 12 months in all
patients with non-ST elevation acute coronary syndrome, as
both patients who had revascularisation and those managed
medically derived benefit in post hoc analyses from the
Clopidogrel in Unstable angina to prevent Recurrent Events
(CURE) trial.6 7 No clinical trial has prospectively evaluated
P2Y12 inhibitors in patients intended for an initial non-invasive
management strategy.
The PLATelet inhibition and patient Outcomes (PLATO) trial
found that the reversibly binding oral P2Y12-inhibitor ticagrelor
was superior to clopidogrel for the prevention of the composite
end point of death from vascular causes, myocardial infarction,
and stroke, as well as vascular death in itself and total death,
without an increase in major bleeding, in a broad population of
patients with acute coronary syndromes starting treatment as
soon as possible after hospital admission.8 A pre-specified
objective of the PLATO trial was to compare ticagrelor and
clopidogrel in the stratum of patients with non-ST elevation
acute coronary syndrome whom, at randomisation, the treating
physician stated as planned for a non-invasive treatment
strategy.9 Selection of a strategy before randomisation provides
the opportunity to do a proper statistical comparison between
the groups.10
Methods
Design overview
The PLATO trial enrolled 18 624 patients from 43 countries
between October 2006 and July 2008. Details of the design,
patients, outcome definitions, and results have been published.8 9
Patients were included if they were admitted to hospital with
ST segment elevation acute coronary syndrome scheduled for
primary percutaneous coronary intervention or non-ST segment
elevation acute coronary syndrome, with onset of symptoms
during the previous 24 hours. For non-ST segment elevation
acute coronary syndrome, at least two of the following three
criteria were required: ST segment depression or transient
elevation of at least 1 mm in two or more contiguous leads; a
positive biomarker indicating myocardial necrosis; and one
additional risk indicator, including age over 60 years, previous
myocardial infarction or coronary artery bypass grafting, carotid
artery disease, previous ischaemic stroke, transient ischaemic
attack, carotid stenosis, cerebral revascularisation, diabetes
mellitus, peripheral artery disease, or chronic renal dysfunction
(creatinine clearance <60 mL/min). The most important
exclusion criteria included contraindication to clopidogrel,
fibrinolytic treatment within 24 hours, need for oral
anticoagulation treatment, need for dialysis, and clinically
important anaemia or thrombocytopenia.
Setting and participants
At the time of randomisation, the treating physician designated
patients as planned for initial invasive management or initial
conservative management in the interactive voice randomisation
system. The investigator answered the following question just
before randomisation: “Concerning this patient, do you intend
to use an invasive strategy, with coronary angiography followed
by revascularisation based on the coronary anatomy, or a
non-invasive strategy?” These designations were considered to
be non-binding but created statistically proper pre hoc subgroups
for this analysis. After randomisation, subsequent decisions to
do angiography and revascularisation based on changes in the
patients’ clinical statuses were not restricted.
Randomisation and interventions
Patients were randomly assigned to ticagrelor or clopidogrel.
Ticagrelor was given in a loading dose of 180 mg followed by
90 mg twice daily. Patients randomised to clopidogrel who had
not received an open label loading dose and had not been taking
clopidogrel for at least five days before randomisation received
a 300 mg loading dose of clopidogrel study drug followed by
75 mg daily. Others continued a maintenance dose of 75 mg
clopidogrel daily. All patients received acetylsalicylic acid
(aspirin) unless they were intolerant of it. The randomised
treatment continued for a minimum of six months and a
maximum of 12 months; the median length of study treatment
in the overall population was 9.1 months.
Outcomes and follow-up
The primary efficacy end point was the composite of death from
vascular causes, myocardial infarction, or stroke.8 9 Secondary
end points included the individual components of the primary
end point; all cause mortality; non-vascular mortality; death
from vascular causes or myocardial infarction, stroke, severe
recurrent cardiac ischaemia, recurrent cardiac ischaemia,
transient ischaemic attack, or other arterial thrombotic event;
stroke subclassified as ischaemic, haemorrhagic, and unknown.
Death from vascular causes included cardiovascular deaths,
cerebrovascular deaths, or any other death for which no
non-vascular cause was clearly documented.
The primary safety end point was PLATO defined total major
bleeding. Definitions of bleeding used in the trial have been
previously published.9 An independent central adjudication
committee, unaware of the group assignments, adjudicated all
primary and secondary end points andmajor andminor bleeding
events. TIMI major bleeding was programmed from the
electronic case report form, using a cut-off point of ≥5 g/dL
haemoglobin, but did not necessarily require clinical evidence
of excessive bleeding after coronary artery bypass grafting.
Statistical analysis
The analysis was a pre-specified stratum of the total trial. We
used univariable Cox proportional hazards models to analyse
the primary and secondary end point results. We present
Kaplan-Meier curves for each treatment group for selected end
points and procedures. We present estimates of the end points
for each treatment group as the Kaplan-Meier rates at 360 days
and total number of events during follow-up.When we analysed
subgroups, we derived the P value for interaction from a Cox
model containing subgroup membership, treatment, and the
subgroup by treatment interaction. We used the intention to
treat principle and SAS version 9.2 for all analyses. We used a
P value of 0.05 as a critical value determining statistical
significance of the overall treatment differences.
Results
Patients
The PLATO trial recruited 18 624 patients with acute coronary
syndrome (with or without ST elevation) from 862 centres in
43 countries between October 2006 and July 2008. At the time
of randomisation, 5216 (28%) patients were specified by the
investigator as being intended for a non-invasive treatment
strategy (fig 1). Of these, 2601 patients were randomised to
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ticagrelor and 2615 to clopidogrel. The median age was 65
years, and 36.5% were women (table 1). The median time from
onset of symptoms to randomisation was 16.6 (interquartile
range 9.1-22.0) hours, and the duration of the randomised
treatment was 276 (175-365) days. Despite the initial intent for
a non-invasive approach, 2183 (41.9%) patients had coronary
angiography during the initial hospital admission, at a median
of 51 hours to in-hospital angiography; 1065 (20.4%) had
in-hospital percutaneous coronary intervention, at a median of
70 hours; and 208 (4.0%) had in-hospital coronary artery bypass
grafting at a median of 12 days (table 2). At the end of
follow-up, 2040 (40%) of the patients had had a
revascularisation procedure; 1514 (72.6%) of these had
percutaneous coronary intervention only, 559 (25.8%) had
coronary artery bypass grafting only, and 33 (1.6%) had both
(fig 2).Most patients were diagnosed as having non-ST elevation
myocardial infarction and unstable angina at discharge, but 451
patients (218 patients in the ticagrelor group and 233 in the
clopidogrel group) had ST elevation myocardial infarction as
their final diagnosis (table 2 and fig 1).
Compared with patients with intended invasive management,
patients with intended non-invasive management were older,
were more often women, and more often had cardiovascular
risk factors such as diabetes, previous myocardial infarction,
heart failure, stroke, and renal and peripheral artery disease
(table 1).11 Furthermore, they had a higher average Thrombolysis
In Myocardial Infarction (TIMI) non ST-elevation myocardial
infarction risk score but less often had a positive troponin test
(table 1). On the basis of the intended non-invasivemanagement,
unfractionated heparin, glycoprotein IIb/IIIa inhibitors, and
bivalirudin were used less often but fondaparinux and low
molecular weight heparin were usedmore often. During hospital
admission, the proportion of patients who had coronary
angiography was less than half, percutaneous coronary
intervention about a quarter, and coronary artery bypass grafting
slightly more than two thirds those of the invasive cohort (table
2).
Outcomes
The incidence of the primary composite end point was
significantly lower with ticagrelor than with clopidogrel (14.3%
v 12.0%; hazard ratio 0.85, 95% confidence interval 0.73 to
1.00; P=0.04). All cause mortality was reduced from 8.2% to
6.1% (hazard ratio 0.75, 0.61 to 0.93; P=0.01) and
cardiovascular mortality from 7.2% to 5.5% (0.76, 0.61 to 0.96;
P=0.02) with use of ticagrelor rather than clopidogrel. The rate
of myocardial infarction and the composite of cardiovascular
death and other thromboembolic events did not differ
significantly between the groups. Rates of stroke were not
significantly different, although numerically more haemorrhagic
strokes occurred in the ticagrelor group (table 3).
Compared with patients with intended invasive treatment,
patients with intended non-invasivemanagement had an initially
lower primary event rate, but the event curves crossed at
approximately 30 days and increased more over time (fig 3).
The benefit for ticagrelor compared with clopidogrel was
consistent between the two cohorts; the hazard ratio was 0.85
(0.85 to 1.00) in the non-invasive cohort and 0.84 (0.75 to 0.94)
in the invasive cohort (P for interaction=0.89). The total
mortality was higher in the intended non-invasive cohort than
in the intended invasive cohort during the entire course of the
study (fig 4), but the relative benefit with ticagrelor was
consistent (hazard ratio 0.75 (0.61 to 0.93) v 0.80 (0.61 to 0.93):
P for interaction=0.64).
Bleeding
We found no statistically significant difference in the rates of
PLATO defined total major bleeding: 11.9% for ticagrelor
treated patients and 10.3% for clopidogrel treated patients
(hazard ratio 1.17, 0.98 to 1.39; P=0.08) (fig 5, table 3). Nor
did we find any significant difference between the randomised
groups when we used the TIMI definition of major bleeding.
The incidence of life threatening or fatal major bleedings did
not differ between the groups. Numerically more intracranial
bleedings occurred in the ticagrelor group, but the difference
was not statistically significant. We found a significantly higher
incidence of PLATO defined other major bleedings and of the
composite of major and minor bleedings in the ticagrelor group
owing to a higher incidence of bleedings related to non-coronary
artery bypass grafting during long term treatment.
Outcome in subgroups
In the overall PLATO population, 7955 patients had non-ST
elevation acute coronary artery syndrome as their final diagnosis.
Among these, 2910 (36.6%) patients were intended for
non-invasive management at the time of randomisation. The
result for ticagrelor compared with clopidogrel in this subgroup
was consistent with the overall results in the non-invasive cohort,
with non-significant diagnosis by treatment interactions for the
primary outcome (P=0.58), mortality (P=0.91), and major
bleeding (P=0.90). Among the intended non-invasivelymanaged
patients, 87 patients in the ticagrelor group were admitted
without persistent ST elevation or new left bundle branch block
but had ST elevation myocardial infarction as their final
diagnosis compared with 103 patients in the clopidogrel group.
Also, among 3948 patients who did not actually have
revascularisation during their hospital admission despite the
initially intendedmanagement strategy (as a post-randomisation
decision), ticagrelor reduced the primary outcome compared
with clopidogrel, consistent with the overall results, from 15.2%
(726) to 12.2% (224) (hazard ratio 0.81, 0.68 to 0.97).
Significant versus insignificant coronary
disease among patients who had in-hospital
angiography
Of all patients (intended invasive and non-invasive) who had
coronary angiography during hospital admission, significant
coronary disease, defined as at least one stenosis greater than
50%, was found in 10 755/11 503 (94%) of those who were
intended for invasive management and in 596/674 (89%) of
those whowere initially intended for non-invasive management.
Patients with no significant disease had numerically lower event
rates compared with those who were discovered to have
significant disease. The primary composite event rate and
mortality were consistently numerically lower in the ticagrelor
group compared with the clopidogrel group, with no increase
in major bleeding, independent of angiographic findings.
Discussion
This substudy of the PLATO trial indicates that treatment with
ticagrelor compared with clopidogrel reduces major ischaemic
events without significantly increasing major bleeding across
the spectrum of management strategies for acute coronary
syndrome. The unique design of the trial, with collection of
information about the intended management strategy at the time
of randomisation, allowed us to investigate the outcome of the
randomised treatments in patients with an intended non-invasive
treatment strategy without interference from post-randomisation
treatment selections. This patient population has been
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under-represented in most clinical trials, and no other oral
platelet inhibitor has been prospectively investigated in the
setting of a primary non-invasive management strategy.
Comparison with other studies
TheGlobal Utilisation of Strategies To prevent Occluded arteries
IV (GUSTO IV) trial prospectively showed a high level of
platelet inhibition achieved with the glycoprotein IIb/IIIa
receptor inhibitor abciximab during 24 or 48 hours compared
with placebo in patients with non-ST elevation acute coronary
syndromewhowere intended for initial medical management.12
However, in contrast to the significant benefit of abciximab that
has been shown in patients with acute coronary syndrome having
percutaneous coronary intervention, abciximab increased the
incidence of bleeding and did not reduce ischaemic end points
in this trial that encouraged an early non-invasive management
strategy.13 Clopidogrel versus placebo in addition to aspirin for
acute coronary syndrome has not been evaluated prospectively
in patients not intended for invasive management. However,
the Clopidogrel in Unstable angina to prevent Recurrent
ischemic Events (CURE) trial showed consistent benefit whether
or not revascularisation was actually done.14 The ongoing
TRILOGY (NCT00699998) trial is investigating the efficacy
and safety of the thienopyridine prasugrel compared with
clopidogrel in patients at high risk selected for medical
management of acute coronary syndrome.
In the PLATO trial, 28% of the total patient population and 37%
of the patients with a final diagnosis of non-ST elevation acute
coronary artery syndrome were designated as planned for initial
non-invasive management by the treating physician. Several
registries and clinical trials have shown that 30-60% of patients
admitted with non-ST elevation acute coronary syndrome in
the Western world do not actually have cardiac catheterisation
during hospital admission and 45-80% of patients do not have
revascularisation.4 5 15 16 The patients in PLATO intended for
non-invasive management had a higher long term event rate
than did those intended for invasive management,11 probably
related in part to their high risk profile at baseline. These
findings are consistent with registry data and post hoc analyses
from clinical trials showing an up to twofold higher event rate
compared with patients who have revascularisation.17 The shape
of the event curves for the primary outcome differed between
the invasive and non-invasive cohorts, with a higher early event
rate in the invasive cohort and crossing event curves reflecting
the different distributions of ST elevation and non-ST elevation
acute coronary syndrome in the two cohorts and peri-procedural
events.
Invasive management
Despite an intended non-invasive strategy at the time of
randomisation, approximately half of the patients had coronary
angiography, a third had percutaneous coronary intervention,
and one tenth had coronary artery bypass grafting during the
course of the study for emerging clinical indications. The relative
reduction of the primary ischaemic end point and mortality by
ticagrelor compared with clopidogrel was independent of the
initial pre-randomisation treatment strategy, without any
significant increase in major bleeding. Although the results in
subgroups based on post-randomisation clinical data and
treatment options have to be interpreted with caution, the benefit
of ticagrelor compared with clopidogrel was consistent with the
overall trial results. Thus, the results were in favour of ticagrelor
whether or not revascularisation was actually done
post-randomisation and whether or not significant coronary
disease was found at any angiography during hospital admission.
Safety
Although rates of PLATO defined overall major bleeding did
not differ significantly between the randomised groups, an
excess of minor bleedings occurred, particularly of those not
related to coronary artery bypass grafting during long term
treatment. We also found a numerical increase in intracerebral
bleedings, although the numbers were very small. The higher
incidence of minor bleedings should be taken into consideration
in patients at low risk not intended for invasive treatment, as
patients at low risk of thromboembolic events have a low
potential benefit frommore extensive antithrombotic treatment
and bleeding complications tend to accrue over time.
Conclusion and implications
In a population of patients with acute coronary syndrome
managed with a planned non-invasive treatment strategy, more
intense P2Y12 receptor inhibition with ticagrelor achieved a
clinically important reduction in ischaemic events andmortality,
but without increasing major bleeding, compared with
clopidogrel. These results indicate the broad benefits of
intensified P2Y12 inhibition for patients with acute coronary
syndrome across management strategies.
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What is already known on this topic
Ticagrelor reduced ischaemic events and mortality compared with clopidogrel, with similar major bleeding rates, through
12 months in the PLATO trial
30-60% of patients admitted with non-ST elevation acute coronary syndrome in the Western world do not have cardiac
catheterisation during hospital admission, and 45-80% do not have revascularisation
No clinical trial has prospectively reported outcomes with P2Y12 inhibitors among patients intended for initial non-invasive
management
What this study adds
In acute coronary syndrome patients initially intended for non-invasive management, ticagrelor achieved a clinically
important reduction in ischaemic events and mortality compared with clopidogrel, without increasing major bleeding
The reduction of ischaemic events andmortality by ticagrelor over clopidogrel was consistent in acute coronary syndrome
patients with non-ST elevation who did not actually have revascularisation
The benefits of intensified P2Y12 inhibition apply across different management strategies
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Tables
Table 1| Patients’ characteristics. Values are percentages (numbers) unless stated otherwise
Planned invasive (n=13 408)
Planned non-invasive
Total (n=5216)Clopidogrel (n=2615)Ticagrelor (n=2601)
Demographics
61 (53-69) (n=13 406)65 (57-73)65 (57-73)66 (57-73)Median (IQR) age (years)
13.2 (1770)21.2 (1108)21.2 (555)21.3 (553)Age ≥75 years
25.2 (3382)36.5 (1906)36.1 (945)36.9 (961)Women
80 (70-90) (n=133 63)78 (69-88) (n=5205)78 (69-88) (n=2608)78 (69-88) (n=2597)Median (IQR) weight (kg)
27.4 (24.8-30.4) (n=133 37)27.3 (24.6-30.4) (n=5195)27.4 (24.6-30.4) (n=2603)27.3 (24.6-30.4) (n=2592)Median (IQR) body mass index
(kg/m2)
Cardiovascular risk factors
39.9 (5349/13 396)25.5 (1329/5214)25.8 (675/2614)25.2 (654/2600)Habitual smoker
62.9 (8422/13 398)72.1 (3761/5215)72.4 (1893)71.8 (1868/2600)Hypertension
46.8 (6275/13 397)46.3 (2414/5215)45.5 (1191)47.0 (1223/2600)Dyslipidaemia
23.2 (3109/13 398)29.8 (1553/5215)28.9 (757)30.6 (796/2600)Diabetes mellitus
Medical history
39.4 (5275/13 398)59.1 (3083/5215)58.7 (1536)59.5 (1547/2600)Angina pectoris
17.0 (2279/13 398)29.6 (1545/5215)30.3 (793)28.9 (752/2600)Myocardial infarction
3.3 (436/13 398)11.8 (614/5215)12.4 (324)11.2 (290/2600)Congestive heart failure
13.7 (1832/13 397)12.7 (660/5215)12.8 (335)12.5 (325/2600)Percutaneous coronary
intervention
5.5 (737/13 398)7.1 (369/5215)7.4 (194)6.7 (175/2600)Coronary artery bypass graft
2.1 (288/13 398)4.0 (211/5215)4.2 (110)3.9 (101/2600)Transient ischaemic attack
3.2 (427/13 398)5.7 (295/5214)5.8 (151/2614)5.5 (144/2600)Non-haemorrhagic stroke
5.5 (743/13 398)7.7 (401/5215)8.0 (210)7.3 (191/2600)Peripheral arterial disease
3.8 (511/13 398)5.3 (274/5215)5.5 (143)5.0 (131/2600)Chronic renal disease
Physical findings
74 (64-84) (n=13 231)72 (64-82) (n=5185)73 (65-82) (n=2601)72 (64-82) (n=2584)Median (IQR) heart rate
133 (120-150) (n=13 231)130 (120-150) (n=5185)130 (120-150) (n=2601)130 (120-150) (n=2584)Median (IQR) systolic blood
pressure
80 (70-90) (n=13 231)80 (70-87) (n=5185)80 (70-86) (n=2601)80 (70-88) (n=2584)Median (IQR) diastolic blood
pressure
Risk indicators
86.9 (11 329/13 042)75.0 (3760/5015)75.4 (1900/2520)74.5 (1860/2495)Troponin positive*
46.4 (6211/13 380)62.9 (3275/5210)64.0 (1673/2613)61.7 (1602/2597)ST depression (≥1 mm)
68.8 (8954/13 006)88.9 (4520/5087)88.5 (2261/2555)89.2 (2259/2532)TIMI NSTE-ACS risk score >2
IQR=interquartile range; TIMI NSTE-ACS=Thrombolysis In Myocardial Infarction non-ST elevation acute coronary syndrome.
*Positive result on testing for troponin I consisted of troponin I concentration ≥0.08 µg/L for first sample taken, as measured at central laboratory with use of Advia
Centaur TnI-Ultra Immunoassay (Siemens).
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Table 2| Treatments and procedures during hospital admission. Values are percentages (numbers) unless stated otherwise
Planned invasive (n=13
408)
Planned non-invasive
Total (n=5216)Clopidogrel (n=2615)Ticagrelor (n=2601)
Type of acute coronary syndrome* at discharge
49.1 (6575/13 380)8.7 (451/5202)8.9 (233/2608)8.4 (218/2594)STEMI
37.7 (5045/13 380)55.9 (2910/5202)56.3 (1469/2608)55.6 (1441/2594)NSTEMI
13.2 (1760/13 380)35.4 (1841/5202)34.7 (906/2608)36.0 (935/2594)Unstable angina pectoris or other
Antithrombotic treatment during initial hospital admission
98.0 (13 128/13 390)94.9 (4947/5211)94.7 (2472/2611)95.2 (2475/2600)Aspirin
66.0 (8844)37.1 (1934)36.7 (959)37.5 (975)Unfractionated heparin
47.1 (6318)63.9 (3331)63.6 (1663)64.1 (1668)Low molecular weight heparin
1.9 (253)4.9 (256)4.8 (125)5.0 (131)Fondaparinux
2.7 (356)0.3 (18)0.4 (10)0.3 (8)Bivalirudin
35.3 (4730)5.9 (307)6.2 (162)5.6 (145)Glycoprotein IIb/IIIa inhibitor
Other drug from randomisation to end of study
85.7 (11 489)84.5 (4406)83.9 (2194)85.0 (2212)β blocker
86.9 (11 637/13 390)83.0 (4324/5211)82.8 (2162/2611)83.2 (2162/2600)ACE inhibitor/angiotensin receptor
blocker
95.3 (12 778)89.8 (4682)89.7 (2345)89.9 (2337)Cholesterol lowering drug (statin)
21.7 (2905)29.8 (1553)30.1 (786)29.5 (767)Calcium antagonist
38.9 (5213/13 390)47.9 (2494/5211)46.8 (1222/2611)48.9 (1272/2600)Diuretic
54.0 (7237)39.5 (2058)39.0 (1020)39.9 (1038)Proton pump inhibitor
Invasive procedures
Coronary angiography:
96.9 (12 987)41.9 (2183)41.9 (1095)41.8 (1088)Before discharge
97.6 (13 085)55.5 (2895)55.4 (1448)55.6 (1447)Any time during follow-up
0.6 (0.1-3.8) (n=13 083)91 (26-240) (n=2891)92 (26-235) (n=1446)89 (26-266) (n=1445)Median (IQR) time to angiography
(hours)
Percutaneous coronary intervention
(PCI):
76.8 (10 298)20.4 (1065)20.5 (537)20.3 (528)Before discharge
78.0 (10 463)29.0 (1514)29.7 (776)28.4 (738)Any time during follow-up
0.8 (0.3-3.0) (n=10 462)141 (41-383) (n=1514)144 (42-391) (n=776)136 (40-379) (n=738)Median (IQR) time to PCI (hours)
Coronary artery bypass grafting
(CABG):
5.7 (762)4.0 (208)3.8 (100)4.2 (108)Before discharge
10.0 (1340)10.7 (559)10.4 (272)11.0 (287)Any time during follow-up
240 (92-1145) (n=1340)623 (307-1742) (n=559)642 (308-1852) (n=272)609 (306-1682) (n=287)Median (IQR) time to CABG (hours)
ACE=angiotensin converting enzyme; IQR=interquartile range; NSTEMI=non-ST segment elevation myocardial infarction; STEMI=ST segment elevation myocardial
infarction.
*Defined by final diagnosis of index event.
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Table 3| Efficacy and safety of treatment. Values are Kaplan-Meier estimates of percentage rate of end point (numbers) at 12 months
P value*Hazard ratio (95% CI)Clopidogrel (n=2615)Ticagrelor (n=2601)
Primary objective
0.0450.85 (0.73 to1.00)14.3 (346)12.0 (295)Cardiovascular death + myocardial infarction (excluding silent) +
stroke
Secondary objectives
0.5550.94 (0.77 to 1.15)7.8 (187)7.2 (176)Myocardial infarction
0.0190.76 (0.61 to 0.96)7.2 (173)5.5 (132)Cardiovascular death
0.0100.75 (0.61 to 0.93)8.2 (195)6.1 (147)All cause death
0.2520.68 (0.35 to 1.31)1.0 (22)0.6 (15)Non-cardiovascular death
0.1621.35 (0.89 to 2.07)1.7 (37)2.1 (50)Stroke:
0.5301.4 (32)1.5 (37)Ischaemic
0.0690.2 (4)0.5 (11)Haemorrhagic
0.1240.06 (1)0.2 (5)Unknown
0.3090.94 (0.82 to 1.06)20.3 (492)18.6 (460)
Cardiovascular death + myocardial infarction + stroke + composite
ischaemic events† + other arterial thrombotic events
Primary safety objective
0.0791.17 (0.98 to 1.39)10.3 (238)11.9 (272)Total major bleeding
0.9110.99 (0.77 to 1.26)5.6 (129)5.5 (125)Life threatening or fatal bleeding
0.0752.83 (0.90 to 8.90)0.2 (4)0.5 (11)Intracranial bleeding
0.0091.38 (1.09 to 1.76)4.9 (114)6.8 (154)Other major bleeding
Secondary safety objectives—components of major bleeding events
0.1031.30 (0.95 to 1.77)3.1 (71)4.0 (90)Non-CABG related
0.3351.11 (0.90 to 1.36)7.5 (174)8.3 (189)CABG related
0.2311.13 (0.93 to 1.37)8.2 (191)9.2 (211)Coronary procedure related
0.0720.15 (0.02 to 1.19)0.4 (7)0.04 (1)Non-coronary procedure related
Secondary safety objectives—major or minor bleeding events
0.03581.17 (1.01 to 1.36)14.4 (332)16.4 (378)Total
0.01821.29 (1.04 to 1.60)6.7 (151)8.3 (190)Non-CABG related
0.63411.05 (0.86 to 1.28)8.5 (196)8.9 (202)CABG related
0.36571.09 (0.91 to 1.30)10.0 (235)10.8 (250)Coronary procedure related
0.36320.70 (0.33 to 1.51)0.8 (16)0.5 (11)Non-coronary procedure related
Other safety objectives
TIMI defined cut-off point for major bleeding:
0.2701.13 (0.91 to 1.39)7.2 (164)7.9 (181)Total
0.1421.33 (0.91 to 1.94)2.2 (47)2.8 (61)Non-CABG related
0.7991.03 (0.80 to 1.33)5.3 (122)5.4 (124)CABG related
Transfusion of blood products:
0.8041.03 (0.83 to 1.27)7.2 (172)7.6 (174)PRBCs or whole blood
0.6451.13 (0.67 to 1.90)1.2 (27)1.3 (30)Platelets
0.5651.12 (0.76 to 1.64)2.2 (50)2.4 (55)Fresh frozen plasma
CABG=coronary artery bypass grafting; PRBC=packed red blood cells; TIMI=Thrombolysis In Myocardial Infarction.
*From univariate Cox model.
†Severe recurrent cardiac ischaemia, recurrent cardiac ischaemia, and transitory ischaemic attack.
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Figures
Fig 1 Flowchart showing number of patients intended for invasive and non-invasive management at time of randomisation,
randomised to ticagrelor or clopidogrel, and final diagnosis at discharge. NSTEMI=non-ST segment myocardial infarction;
STEMI=ST segment myocardial infarction
Fig 2Cumulative incidence of cardiac catheterisation, percutaneous coronary intervention (PCI) and coronary artery bypass
grafting (CABG) in patients intended for non-invasive management and randomised to ticagrelor or clopidogrel
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Fig 3 Cumulative incidence of primary composite of cardiovascular death, myocardial infarction (MI), and stroke in ticagrelor
and clopidogrel groups in patients intended for invasive and non-invasive management at time of randomisation
Fig 4 Cumulative incidence of total mortality in ticagrelor and clopidogrel groups in patients intended for invasive and
non-invasive management at time of randomisation
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Fig 5 Cumulative incidence of major bleeding in ticagrelor and clopidogrel groups in patients intended for invasive and
non-invasive management at time of randomisation
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